title: A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
abstract: BACKGROUND
  Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with advanced gastric carcinoma (AGC).
  
  
  METHODS
  In this prospective, randomized, multicenter Phase III study, previously untreated patients with histopathologically proven AGC enrolled after giving informed consent. Patients were allocated to receive either EEP (etoposide 120 mg/m2, epirubicin 30 mg/m2, and cisplatin 40 mg/m2 on Days 1 and 8) or FEP (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and cisplatin 80 mg/m2 on Day 1), and the regimens were to be repeated every fourth week.
  
  
  RESULTS
  Of a total of 131 eligible patients, 64 were in the EEP group and 67 were in the FEP group. The objective response (complete + partial) rates for evaluable patients (n = 118) were comparable (P = 0.63) in the EEP (20.3%, 12/59) and FEP (15.3%, 9/59) groups, respectively. Actuarial analyses revealed comparable median progression free survival (6 vs. 7 months, P > 0.05) and overall survival (6 vs. 5 months, P > 0.05) duration in the EEP and FEP groups. Both regimens were well tolerated. The most common toxicity was Grade 1-2 nausea with or without vomiting. No chemotherapy-related death occurred.
  
  
  CONCLUSIONS
  The current study resulted in inadequate response rates for EEP and FEP regimens. Neither combination, as used at the doses and schedules in this study, can be recommended as standard treatment for patients with AGC.
authors.affiliation: Department of Medical Oncology, Ankara University, Turkey.
authors.forename: F
authors.initials: F
authors.lastname: Içli
authors.forename: I
authors.initials: I
authors.lastname: Celik
authors.forename: F
authors.initials: F
authors.lastname: Aykan
authors.forename: A
authors.initials: A
authors.lastname: Uner
authors.forename: A
authors.initials: A
authors.lastname: Demirkazik
authors.forename: A
authors.initials: A
authors.lastname: Ozet
authors.forename: M
authors.initials: M
authors.lastname: Ozgüroğlu
authors.forename: F
authors.initials: F
authors.lastname: Taş
authors.forename: H
authors.initials: H
authors.lastname: Akbulut
authors.forename: D
authors.initials: D
authors.lastname: Firat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012044:Regression Analysis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin; D005472:Fluorouracil